Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline LlcfiledCriticalGlaxosmithkline Llc
Priority claimed from PCT/US2013/071376external-prioritypatent/WO2014081994A1/en
Publication of MA38102A1publicationCriticalpatent/MA38102A1/en
Publication of MA38102B1publicationCriticalpatent/MA38102B1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
L'invention concerne de nouveaux composés qui sont des inhibiteurs d'acyl-coenzyme a: diacylglycérol transférase 1 (dgat1), des compositions pharmaceutiques les contenant, des procédés pour leur préparation, ainsi que leur utilisation en thérapie, seuls ou en combinaison avec des thérapies de gestion du poids ou autre thérapie de diminution des triglycérides pour la prévention ou le traitement de maladies liées à un dysfonctionnement de dgat1 ou dans lesquelles une modulation de l'activité de dgat1 peut avoir un bénéfice thérapeutique.The invention relates to novel compounds which are acyl-coenzyme a: diacylglycerol transferase 1 (dgat1) inhibitors, pharmaceutical compositions containing them, processes for their preparation and their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat1 dysfunction or in which modulation of dgat1 activity may be of therapeutic benefit.
MA38102A2013-10-252013-11-22
Novel compounds used as inhibitors of diacylglycerol acyltransferase
MA38102B1
(en)
N- [4- (quinolin-4-yloxy) cyclohexyl (methyl)] (hetero) arylcarboxamides for use as androgen receptor antagonists, their production and their use as medicaments